$BIOLQ
BIOLASE, INC

2021 Q1 Form 10-Q Financial Statement

#000095017021000226 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $8.116M $4.783M
YoY Change 69.68% -53.68%
Cost Of Revenue $5.375M $3.430M
YoY Change 56.71% -49.56%
Gross Profit $2.741M $1.353M
YoY Change 102.59% -61.56%
Gross Profit Margin 33.77% 28.29%
Selling, General & Admin $6.911M $5.714M
YoY Change 20.95% -8.87%
% of Gross Profit 252.13% 422.32%
Research & Development $1.803M $991.0K
YoY Change 81.94% -30.21%
% of Gross Profit 65.78% 73.24%
Depreciation & Amortization $85.00K $177.0K
YoY Change -51.98% -31.4%
% of Gross Profit 3.1% 13.08%
Operating Expenses $8.803M $6.705M
YoY Change 31.29% -12.92%
Operating Profit -$6.062M -$5.352M
YoY Change 13.27% 28.04%
Interest Expense -$575.0K $589.0K
YoY Change -197.62% -223.22%
% of Operating Profit
Other Income/Expense, Net -$779.0K $673.0K
YoY Change -215.75% -229.17%
Pretax Income -$6.841M -$6.025M
YoY Change 13.54% 23.34%
Income Tax $60.00K -$19.00K
% Of Pretax Income
Net Earnings -$6.901M -$6.006M
YoY Change 14.9% 22.57%
Net Earnings / Revenue -85.03% -125.57%
Basic Earnings Per Share -$0.06 -$0.19
Diluted Earnings Per Share -$0.06 -$0.19
COMMON SHARES
Basic Shares Outstanding 134.6M 31.51M
Diluted Shares Outstanding 134.6M 31.51M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.84M $1.510M
YoY Change 2604.64% -48.99%
Cash & Equivalents $40.84M $1.823M
Short-Term Investments
Other Short-Term Assets $1.760M $1.520M
YoY Change 15.79% -28.64%
Inventory $11.88M $12.19M
Prepaid Expenses
Receivables $3.300M $4.750M
Other Receivables $0.00 $0.00
Total Short-Term Assets $57.75M $19.97M
YoY Change 189.18% -30.78%
LONG-TERM ASSETS
Property, Plant & Equipment $693.0K $1.150M
YoY Change -39.74% -52.67%
Goodwill $2.900M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $226.0K $484.0K
YoY Change -53.31% -221.0%
Total Long-Term Assets $5.735M $4.561M
YoY Change 25.74% -8.04%
TOTAL ASSETS
Total Short-Term Assets $57.75M $19.97M
Total Long-Term Assets $5.735M $4.561M
Total Assets $63.48M $24.53M
YoY Change 158.79% -27.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.072M $4.056M
YoY Change -24.26% -31.14%
Accrued Expenses $600.0K $4.079M
YoY Change -85.29% -29.91%
Deferred Revenue $1.961M $1.982M
YoY Change -1.06% -21.13%
Short-Term Debt $0.00 $13.56M
YoY Change -100.0%
Long-Term Debt Due $0.00 $13.56M
YoY Change -100.0%
Total Short-Term Liabilities $11.27M $23.68M
YoY Change -52.41% 56.61%
LONG-TERM LIABILITIES
Long-Term Debt $16.30M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $77.00K $1.107M
YoY Change -93.04% 583.33%
Total Long-Term Liabilities $16.37M $1.107M
YoY Change 1378.95% -90.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.27M $23.68M
Total Long-Term Liabilities $16.37M $1.107M
Total Liabilities $29.97M $25.42M
YoY Change 17.88% -5.28%
SHAREHOLDERS EQUITY
Retained Earnings -$258.3M -$240.6M
YoY Change 7.37%
Common Stock $292.3M $236.4M
YoY Change 23.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.52M -$4.856M
YoY Change
Total Liabilities & Shareholders Equity $63.48M $24.53M
YoY Change 158.79% -27.44%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$6.901M -$6.006M
YoY Change 14.9% 22.57%
Depreciation, Depletion And Amortization $85.00K $177.0K
YoY Change -51.98% -31.4%
Cash From Operating Activities -$6.499M -$4.134M
YoY Change 57.21% -17.88%
INVESTING ACTIVITIES
Capital Expenditures $8.000K $9.000K
YoY Change -11.11% 12.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$8.000K -$9.000K
YoY Change -11.11% 12.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.83M -117.0K
YoY Change -25591.45% -4000.0%
NET CHANGE
Cash From Operating Activities -6.499M -4.134M
Cash From Investing Activities -8.000K -9.000K
Cash From Financing Activities 29.83M -117.0K
Net Change In Cash 23.17M -4.278M
YoY Change -641.61% -15.92%
FREE CASH FLOW
Cash From Operating Activities -$6.499M -$4.134M
Capital Expenditures $8.000K $9.000K
Free Cash Flow -$6.507M -$4.143M
YoY Change 57.06% -17.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PrepaidExpenseAndOtherAssetsCurrent
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000811240
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 biol Operating Lease Weighted Average Remaining Lease Terms
OperatingLeaseWeightedAverageRemainingLeaseTerms
CY2021Q1 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-36385
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
BIOLASE, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
27042 Towne Centre Drive
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Lake Forest
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92610
CY2021Q1 dei City Area Code
CityAreaCode
949
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
361-1200
CY2021Q1 dei Security12b Title
Security12bTitle
Common stock at par value $0.001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
BIOL
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
150399159
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40842000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17564000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
204000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
312000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3908000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4017000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3266000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3059000
CY2021Q1 us-gaap Inventory Net
InventoryNet
11877000
CY2020Q4 us-gaap Inventory Net
InventoryNet
11157000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1560000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3018000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
57749000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
35110000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
693000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
782000
CY2021Q1 us-gaap Goodwill
Goodwill
2926000
CY2020Q4 us-gaap Goodwill
Goodwill
2926000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1890000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1976000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
226000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
231000
CY2021Q1 us-gaap Assets
Assets
63484000
CY2020Q4 us-gaap Assets
Assets
41025000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6667000
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1961000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1905000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11270000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11223000
CY2021Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
343000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
374000
CY2021Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
297000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3072000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2651000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6237000
CY2020Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
384000
CY2021Q1 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
16295000
CY2020Q4 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
16186000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1686000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1774000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
77000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1056000
CY2021Q1 us-gaap Liabilities
Liabilities
29968000
CY2020Q4 us-gaap Liabilities
Liabilities
30997000
CY2021Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2021Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
18000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
18000
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
36000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
118000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
149427000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97709000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
149382000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97663000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
149000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
98000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
292141000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
261573000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
991000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
8803000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-533000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-385000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-258277000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251376000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
33516000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10028000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63484000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41025000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8116000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4783000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
5375000
CY2020Q1 us-gaap Cost Of Revenue
CostOfRevenue
3430000
CY2021Q1 us-gaap Gross Profit
GrossProfit
2741000
CY2020Q1 us-gaap Gross Profit
GrossProfit
1353000
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3553000
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2704000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3447000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3010000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1803000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
6705000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6062000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5352000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
204000
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
84000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
575000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
589000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
779000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
673000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6841000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6025000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-19000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6901000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6006000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-148000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-18000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7049000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6024000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6901000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6006000
CY2021Q1 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
-532000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7433000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6006000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
33516000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
177000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
377000
CY2020Q1 biol Adjustments To Additional Paid In Capital Settlement Of Liability Awards
AdjustmentsToAdditionalPaidInCapitalSettlementOfLiabilityAwards
151000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
640000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6006000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-18000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-4856000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-6901000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-6006000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
85000
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
134586000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31509000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134586000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31509000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10028000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13292000
CY2021Q1 biol Issuance Of Common Stock For Settlement Of Liability
IssuanceOfCommonStockForSettlementOfLiability
510000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1695000
CY2021Q1 biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
15040000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6901000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-148000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-106000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
987000
CY2021Q1 biol Provision For Sales Returns
ProvisionForSalesReturns
90000
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
-20000
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
10000
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
42000
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
46000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
95000
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
50000
CY2021Q1 biol Patent Litigation Mark To Market
PatentLitigationMarkToMarket
89000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
928000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
719000
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-32000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
193000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3024000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
700000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1207000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-558000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
142000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-488000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1541000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
22000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-219000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6499000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4134000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13292000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6000
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
117000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16539000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29825000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-117000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-148000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-18000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23170000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4278000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17876000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6101000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41046000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1823000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
448000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
485000
CY2021Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
14000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
10000
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
28000
CY2021Q1 biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
66000
CY2020Q1 biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
192000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000
CY2021Q1 biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
510000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41000000.0
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3300000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14400000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16500000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="padding-top:6.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="padding-top:6.0pt;text-indent:24.5pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.</span></p>
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="padding-top:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="padding-top:6.0pt;text-indent:24.5pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers’ financial condition and maintains relationships with the Company’s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of products.</span></p><p style="padding-top:12.0pt;text-indent:24.5pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Substantially all of the Company’s revenue is denominated in U.S. dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company’s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the three-month periods ended March 31, 2021 and 2020, respectively, the Company did not enter into any</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="padding-top:12.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">hedging contracts. Future fluctuations in the value of the U.S. dollar may affect the price competitiveness of the Company’s products outside the U.S.</span></p>
CY2021Q1 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.88
CY2020Q1 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.74
CY2021Q1 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.12
CY2020Q1 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.26
CY2021Q1 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
700000
CY2020Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
700000
CY2021Q1 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
706000
CY2020Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
670000
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.03
CY2021Q1 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
14400000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q1 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
900000
CY2020Q1 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
700000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
700000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100000
CY2021Q1 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1598000
CY2020Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1609000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2304000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2279000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
343000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
374000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1961000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1905000
CY2021Q1 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
500000
CY2020Q1 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
100000
CY2021Q1 biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
500000
CY2020Q1 biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
1000000.0
CY2021Q1 biol Deferred Royalties
DeferredRoyalties
0
CY2020Q1 biol Deferred Royalties
DeferredRoyalties
0
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8116000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4783000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8116000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4783000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8116000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4783000
CY2021Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14000000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.82
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0069
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0125
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2398000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.96
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
53000
CY2021Q1 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
20000
CY2021Q1 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
1.29
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
9000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M12D
CY2021Q1 biol Share Based Compensation Arrangement By Share Based Payment Award Recognized Weighted Average Expected Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardRecognizedWeightedAverageExpectedDate
2022-06
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
928000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
719000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.10
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.88
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2409000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.95
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
589000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1083000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.01
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y3M18D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.07
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.54
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
21000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
67000
CY2021Q1 biol Proceeds From Warrant Exercise
ProceedsFromWarrantExercise
15000000.0
CY2020Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1500000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25290000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3400000000
CY2021Q1 biol Temporary Equity Conversion Of Preferred Stock Into Common Stock
TemporaryEquityConversionOfPreferredStockIntoCommonStock
268
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
3998000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3721000
CY2021Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1462000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1158000
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6417000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6278000
CY2021Q1 us-gaap Inventory Net
InventoryNet
11877000
CY2020Q4 us-gaap Inventory Net
InventoryNet
11157000
CY2021Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
700000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
700000
CY2021Q1 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8264000
CY2020Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8269000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7741000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7664000
CY2021Q1 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
523000
CY2020Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
605000
CY2021Q1 us-gaap Land
Land
170000
CY2020Q4 us-gaap Land
Land
177000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
693000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
782000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2020 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2021Q1 us-gaap Goodwill
Goodwill
2900000
CY2020Q4 us-gaap Goodwill
Goodwill
2900000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2573000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3552000
CY2021Q1 biol Settlement Liability Accrual Classified Current
SettlementLiabilityAccrualClassifiedCurrent
579000
CY2020Q4 biol Settlement Liability Accrual Classified Current
SettlementLiabilityAccrualClassifiedCurrent
0
CY2021Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1099000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
748000
CY2021Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
346000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
165000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
263000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
281000
CY2021Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
532000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
885000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
340000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
305000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
505000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
731000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6237000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6667000
CY2021Q1 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
400000
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1132000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1110000
CY2021Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
664000
CY2020Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
203000
CY2021Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
400000
CY2020Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
156000
CY2021Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1396000
CY2020Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1157000
CY2021Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
297000
CY2020Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
246000
CY2021Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1099000
CY2020Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
911000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
16295000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
16186000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16295000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16186000
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
CY2021Q1 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.1225
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2021Q1 biol Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
1344000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
5080000
CY2021Q1 biol Long Term Debt Maturities Repayments Of Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
1755000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2803000
CY2021Q1 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
1393000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
9403000
CY2021Q1 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
1900000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
3000
CY2021Q1 biol Long Term Debt Maturities Repayments Of Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearFour
9000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
141000
CY2021Q1 biol Long Term Debt Maturities Repayments Of Interest In Year After Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFive
73000
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
17430000
CY2021Q1 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
6474000
biol Warrants Adjusted Exercise Price
WarrantsAdjustedExercisePrice
0.60
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2021Q1 biol Lease Facility Area
LeaseFacilityArea
11000
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-12-31
CY2020Q1 biol Lease Facility Area
LeaseFacilityArea
11000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
66000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
192000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1890000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021Q1 biol Operating Lease Weighted Average Remaining Lease Terms
OperatingLeaseWeightedAverageRemainingLeaseTerms
P4Y6M
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
583000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
577000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
587000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
563000
CY2021Q1 biol Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
367000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2676000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
650000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2026000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
340000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1686000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2026000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1900000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000.0
CY2021Q1 us-gaap Payments For Rent
PaymentsForRent
200
CY2020Q1 us-gaap Payments For Rent
PaymentsForRent
200
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
440000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
573000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
587000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
587000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
489000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2676000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
650000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2026000
CY2021Q1 biol Litigation Settlement Shares Issued
LitigationSettlementSharesIssued
500000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
600000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8116000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4783000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
693000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
782000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8116000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4783000
CY2021Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2020Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-19000
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.009
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
CY2021Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0000950170-21-000226-index-headers.html Edgar Link pending
0000950170-21-000226-index.html Edgar Link pending
0000950170-21-000226.txt Edgar Link pending
0000950170-21-000226-xbrl.zip Edgar Link pending
biol-20210331-ex31_1.htm Edgar Link pending
biol-20210331-ex32_1.htm Edgar Link pending
biol-20210331.htm Edgar Link pending
biol-20210331.xsd Edgar Link pending
biol-20210331_cal.xml Edgar Link unprocessable
biol-20210331_def.xml Edgar Link unprocessable
biol-20210331_htm.xml Edgar Link completed
biol-20210331_lab.xml Edgar Link unprocessable
biol-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending